Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

The US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC).

The results of the baseline economic analysis by test strategy were as follows ... The results are not sensitive to varying levels of HER2 overexpression in the population, as shown for a US$ ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...

whereas the serum-based HER2 assay is a dynamic, real-time test that requires only a blood sample. The serum-based HER2 test, approved by the US FDA, is intended to measure soluble HER2 ...

The availability of a simple immunohistochemical (IHC) test for HER2-low status is seen as critical to the successful rollout of Enhertu (trastuzumab deruxtecan) in this category of breast cancer ...

HER2 is a protein that is associated with many cancers, and HER2 tumour marker testing is used to determine if targeted therapy will be effective. A quantitative HER2 test, that objectively ...

Results of HER2DX testing showed that patients whose risk ... that one year of T-DM1 after surgery for patients with a stage 1 HER2-positive cancer leads to outstanding long term outcomes, making ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...